JP2023535483A - 脳組織中のスフィンゴ糖脂質濃度を低減させるための方法およびそれを含む神経変性疾患の処置方法 - Google Patents

脳組織中のスフィンゴ糖脂質濃度を低減させるための方法およびそれを含む神経変性疾患の処置方法 Download PDF

Info

Publication number
JP2023535483A
JP2023535483A JP2023505841A JP2023505841A JP2023535483A JP 2023535483 A JP2023535483 A JP 2023535483A JP 2023505841 A JP2023505841 A JP 2023505841A JP 2023505841 A JP2023505841 A JP 2023505841A JP 2023535483 A JP2023535483 A JP 2023535483A
Authority
JP
Japan
Prior art keywords
subject
disease
compound
parkinson
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023505841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535483A5 (https=
Inventor
ターニャ・ザレンバ・フィッシャー
ジュディス・ピーターシュミット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2023535483A publication Critical patent/JP2023535483A/ja
Publication of JP2023535483A5 publication Critical patent/JP2023535483A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023505841A 2020-07-30 2021-07-30 脳組織中のスフィンゴ糖脂質濃度を低減させるための方法およびそれを含む神経変性疾患の処置方法 Pending JP2023535483A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063059047P 2020-07-30 2020-07-30
US63/059,047 2020-07-30
US202063131120P 2020-12-28 2020-12-28
US63/131,120 2020-12-28
PCT/IB2021/056971 WO2022024062A1 (en) 2020-07-30 2021-07-30 Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same

Publications (2)

Publication Number Publication Date
JP2023535483A true JP2023535483A (ja) 2023-08-17
JP2023535483A5 JP2023535483A5 (https=) 2024-08-06

Family

ID=77265125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023505841A Pending JP2023535483A (ja) 2020-07-30 2021-07-30 脳組織中のスフィンゴ糖脂質濃度を低減させるための方法およびそれを含む神経変性疾患の処置方法

Country Status (11)

Country Link
US (1) US20230372313A1 (https=)
EP (1) EP4188381A1 (https=)
JP (1) JP2023535483A (https=)
KR (1) KR20230047146A (https=)
CN (1) CN116322679A (https=)
AU (1) AU2021317180A1 (https=)
BR (1) BR112023001362A2 (https=)
CA (1) CA3187086A1 (https=)
IL (1) IL300096A (https=)
MX (1) MX2023001285A (https=)
WO (1) WO2022024062A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
KR20260021150A (ko) 2024-08-05 2026-02-13 충북대학교 산학협력단 Gba1 돌연변이 보인자의 dj-1 발현수준에 따른 파킨슨병의 위험도 예측 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517808A (ja) * 2011-03-18 2014-07-24 ジェンザイム・コーポレーション グルコシルセラミド合成酵素阻害剤
JP2018507886A (ja) * 2015-03-10 2018-03-22 ジェンザイム・コーポレーション タンパク質症を処置するための方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
US10617713B2 (en) * 2016-03-08 2020-04-14 Neurocentria, Inc. Methods of modifying neuronal function by changing intracellular magnesium levels
EP3452045A1 (en) * 2016-05-04 2019-03-13 Lysosomal Therapeutics Inc. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
US10519157B2 (en) * 2018-02-09 2019-12-31 X-Cutag Therapeutics, Inc. Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014517808A (ja) * 2011-03-18 2014-07-24 ジェンザイム・コーポレーション グルコシルセラミド合成酵素阻害剤
JP2018507886A (ja) * 2015-03-10 2018-03-22 ジェンザイム・コーポレーション タンパク質症を処置するための方法

Also Published As

Publication number Publication date
WO2022024062A1 (en) 2022-02-03
CN116322679A (zh) 2023-06-23
EP4188381A1 (en) 2023-06-07
MX2023001285A (es) 2023-02-22
BR112023001362A2 (pt) 2023-02-14
IL300096A (en) 2023-03-01
AU2021317180A1 (en) 2023-03-23
US20230372313A1 (en) 2023-11-23
KR20230047146A (ko) 2023-04-06
CA3187086A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
JP7374149B2 (ja) タンパク質症を処置するための方法
US12215111B2 (en) Imidazopyridazine IL-17 inhibitor compounds
US20250042907A1 (en) Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
JP2022530967A (ja) 多形化合物およびその使用
JP2023512366A (ja) リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
JP2025072556A (ja) リソソーム蓄積性疾患と関連する症状および障害を処置するための方法
JP2023535483A (ja) 脳組織中のスフィンゴ糖脂質濃度を低減させるための方法およびそれを含む神経変性疾患の処置方法
KR102472011B1 (ko) App 의 정상 가공을 촉진하는 화합물
US20220087967A1 (en) Sulfopropanoic acid derivatives for treating neurodegenerative disorders
US20240018146A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
RU2853560C1 (ru) Способы снижения концентрации гликосфинголипидов в ткани головного мозга и способы лечения нейродегенеративных заболеваний, их предусматривающие
CN114728920A (zh) 一种沃替西汀前药及其应用
CA3120639A1 (en) Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
RU2824599C2 (ru) Способы лечения симптомов и нарушений, ассоциированных с лизосомными болезнями накопления
RU2829786C2 (ru) Способы лечения симптомов и нарушений, ассоциированных с лизосомными болезнями накопления
KR20250047213A (ko) 질소 함유 헤테로고리 화합물의 다형체 및 그의 용도
WO2024091523A1 (en) Conformationally restricted phenethylamine analogs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260113